» Articles » PMID: 32394474

HBV-Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2020 May 13
PMID 32394474
Citations 79
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Epitranscriptomic modification of RNA has emerged as the most prevalent form of regulation of gene expression that affects development, differentiation, metabolism, viral infections, and most notably cancer. We have previously shown that hepatitis B virus (HBV) transcripts are modified by N6 methyladenosine (m A) addition. HBV also affects m A modification of several host RNAs, including phosphatase and tensin homolog (PTEN), a well-known tumor suppressor. PTEN plays a critical role in antiviral innate immunity and the development of hepatocellular carcinoma (HCC). Reports have shown that PTEN controlled interferon regulatory factor 3 (IRF-3) nuclear localization by negative phosphorylation of IRF-3 at Ser97, and PTEN reduced carcinogenesis by inhibiting the phosphatidylinositol-3-kinase (PI3K)/AKT pathway.

Approach And Results: Here, we show that HBV significantly increases the m A modification of PTEN RNA, which contributes to its instability with a corresponding decrease in PTEN protein levels. This is reversed in cells in which the expression of m A methyltransferases is silenced. PTEN expression directly increases activated IRF-3 nuclear import and subsequent interferon synthesis. In the absence of PTEN, IRF-3 dephosphorylation at the Ser97 site is decreased and interferon synthesis is crippled. In chronic HBV patient biopsy samples, m A-modified PTEN mRNA levels were uniformly up-regulated with a concomitant decrease of PTEN mRNA levels. HBV gene expression also activated the PI3K/AKT pathway by regulating PTEN mRNA stability in HCC cell lines.

Conclusions: The m A epitranscriptomic regulation of PTEN by HBV affects innate immunity by inhibiting IRF-3 nuclear import and the development of HCC by activating the PI3K/AKT pathway. Our studies collectively provide new insights into the mechanisms of HBV-directed immune evasion and HBV-associated hepatocarcinogenesis through m A modification of the host PTEN mRNAs.

Citing Articles

mA modification: a new avenue for anti-cancer therapy.

Bai Y, Li K, Peng J, Yi C Life Med. 2025; 2(1):lnad008.

PMID: 39872957 PMC: 11749794. DOI: 10.1093/lifemedi/lnad008.


The diverse landscape of RNA modifications in cancer development and progression.

Kim H, Eun J, Jang S, Kim J, Jeong J Genes Genomics. 2024; 47(2):135-155.

PMID: 39643826 DOI: 10.1007/s13258-024-01601-y.


METTL14 Induced N-Methyladenosine Modification of FOXP4 mRNA in HBV-HCC.

Wang T, Ji Y, Zhang Q, Liang B, Fan T, Ye X J Cancer. 2024; 15(19):6232-6238.

PMID: 39513116 PMC: 11540497. DOI: 10.7150/jca.101385.


Epigenetic modification of hepatitis B virus infection and related hepatocellular carcinoma.

Zhang Y, Cao W, Wang S, Zhang L, Li X, Zhang Z Virulence. 2024; 15(1):2421231.

PMID: 39460469 PMC: 11583590. DOI: 10.1080/21505594.2024.2421231.


New insights into the impact of impaired epigenetic machinery on liver cancer malignant phenotype.

Marijuan R, Marin J Transl Cancer Res. 2024; 13(9):4514-4519.

PMID: 39430862 PMC: 11483460. DOI: 10.21037/tcr-24-751.